Key result
A FRET-based whole-cell lysate RNase H2 activity assay demonstrated methodological variability of 8.6% to 16% and detected reduced activity in three patients with autoimmune diseases.
Why the study?
RNase H2 loss contributes to autoinflammatory, autoimmune, and other diseases, but no method for quantifying RNase H2 activity had been validated for the clinical setting.
Design
Assay validation and benchmarking study
Authors
Loading...
May support RNase H2 screening in autoimmune diseases; leaves open clinical adoption pending larger validation.
A newly validated FRET-based assay enables standardized quantification of RNase H2 activity in clinical samples, showing potential for screening in autoimmune diseases.
Schulz et al. (2023) studied Systemic lupus erythematosus and systemic sclerosis (n=3). FRET-based whole-cell lysate RNase H2 activity assay was evaluated on Methodological assay variability. A FRET-based whole-cell lysate RNase H2 activity assay demonstrated methodological variability of 8.6% to 16% and detected reduced activity in three patients with autoimmune diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: